Trupti Lingaraj

2.3k total citations
14 papers, 279 citations indexed

About

Trupti Lingaraj is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Trupti Lingaraj has authored 14 papers receiving a total of 279 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Surgery. Recurrent topics in Trupti Lingaraj's work include Cancer-related gene regulation (4 papers), Epigenetics and DNA Methylation (3 papers) and RNA modifications and cancer (2 papers). Trupti Lingaraj is often cited by papers focused on Cancer-related gene regulation (4 papers), Epigenetics and DNA Methylation (3 papers) and RNA modifications and cancer (2 papers). Trupti Lingaraj collaborates with scholars based in United States, France and United Kingdom. Trupti Lingaraj's co-authors include J. Joshua Smith, Allison E. Drew, Scott Ribich, Robert A. Copeland, Candice L. Horn, James E. Thomas, James A. Cook, Timothy I. Meier, Jeffrey A Radding and Michèle C. Smith and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Trupti Lingaraj

11 papers receiving 271 citations

Peers

Trupti Lingaraj

ONCOL

GENET

IMMUN

Sonia C. Maggio United States

Paul M.C. Park United States

Miriam Kull Germany

Elena Ceccacci Italy

Jacob V. Layer United States

Grace Wing-Yan Mak Hong Kong

Constantin Cretu Germany

Junghui Koo United States

Emma Johnson United Kingdom

Kıvanç Görgülü Germany

Sonia C. Maggio United States

Trupti Lingaraj

267 ×1.2

77 ×1.4

ONCOL

15 ×0.5

20 ×1.0

GENET

19 ×0.9

IMMUN

Citations per year, relative to Trupti Lingaraj Trupti Lingaraj (= 1×) peers Sonia C. Maggio

Countries citing papers authored by Trupti Lingaraj

Since Specialization

Citations

This map shows the geographic impact of Trupti Lingaraj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trupti Lingaraj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trupti Lingaraj more than expected).

Fields of papers citing papers by Trupti Lingaraj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Trupti Lingaraj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trupti Lingaraj. The network helps show where Trupti Lingaraj may publish in the future.

Co-authorship network of co-authors of Trupti Lingaraj

This figure shows the co-authorship network connecting the top 25 collaborators of Trupti Lingaraj. A scholar is included among the top collaborators of Trupti Lingaraj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trupti Lingaraj. Trupti Lingaraj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Tolcher, Anthony W., Nehal J. Lakhani, Meredith McKean, et al.. (2025). Abstract CT268: Preliminary results from a first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors. Cancer Research. 85(8_Supplement_2). CT268–CT268.

Aggen, David H., Meredith McKean, Jean Hoffman‐Censits, et al.. (2024). IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.. Journal of Clinical Oncology. 42(16_suppl). 2599–2599.

McKean, Meredith, David H. Aggen, Nehal J. Lakhani, et al.. (2022). Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). TPS3169–TPS3169. 8 indexed citations

Aggen, David H., Meredith McKean, Nehal J. Lakhani, et al.. (2022). 661 Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma. Regular and Young Investigator Award Abstracts. A692–A692. 3 indexed citations

Tolcher, Anthony W., Nehal J. Lakhani, Meredith McKean, et al.. (2022). A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS3168–TPS3168. 28 indexed citations

Gounder, Mrinal M., Silvia Stacchiotti, Patrick Schöffski, et al.. (2020). Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma.. Journal of Clinical Oncology. 38(15_suppl). 11564–11564. 2 indexed citations

Drew, Allison E., Trupti Lingaraj, Natalie M. Warholic, et al.. (2017). EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL. Molecular Cancer Therapeutics. 16(11). 2586–2597. 52 indexed citations

Mitchell, Lorna H., Allison E. Drew, Scott Ribich, et al.. (2015). Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Medicinal Chemistry Letters. 6(6). 655–659. 95 indexed citations

Johnston, Danielle, Christopher Plescia, Trupti Lingaraj, et al.. (2015). Abstract B85: EZH2 plays a critical role in B-cell maturation and in non-Hodgkin's lymphoma: Interplay between EZH2 function and B-cell activation. Molecular Cancer Therapeutics. 14(12_Supplement_2). B85–B85. 1 indexed citations

10.

Gavin, James M., Hua Liao, Xiaofeng Yang, et al.. (2012). Mechanistic Studies on Activation of Ubiquitin and Di-ubiquitin-like Protein, FAT10, by Ubiquitin-like Modifier Activating Enzyme 6, Uba6. Journal of Biological Chemistry. 287(19). 15512–15522. 31 indexed citations

11.

Sappal, Darshan S., Neil Bence, Paul Fleming, et al.. (2011). Cellular and biochemical characterization of an inhibitor of the Ubiquitin Activating Enzyme (UAE). 2. 1 indexed citations

12.

Lingaraj, Trupti, John Donovan, Zhi Li, et al.. (2008). A High-Throughput Liposome Substrate Assay with Automated Lipid Extraction Process for PI 3-Kinase. SLAS DISCOVERY. 13(9). 906–911. 8 indexed citations

13.

Meier, Timothy I., James A. Cook, James E. Thomas, et al.. (2004). Cloning, expression, purification and characterization of the human class Ia phosphoinositide 3-kinase isoforms.. Cancer Research. 64. 813–813. 14 indexed citations

14.

Meier, Timothy I., James A. Cook, James E. Thomas, et al.. (2004). Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms. Protein Expression and Purification. 35(2). 218–224. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact